4.7 Article

Agammaglobulinemia with normal B-cell numbers in a patient lacking Bob1

期刊

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
卷 147, 期 5, 页码 1977-1980

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.jaci.2021.01.027

关键词

-

资金

  1. German Research Foundation (DFG) [SFB1160]
  2. DFG under Germany`s Excellence Strategy [CIBSS-EXC-2189, 390939984]
  3. Children's Hospital of Philadelphia through the Epilepsy NeuroGenetics Initiative
  4. DFG [HE5415/5-1, HE5415/6-1, FOR2715 (HE5415/7-1)]
  5. Else Kroner-Fresenius-Stiftung

向作者/读者索取更多资源

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Review Biochemistry & Molecular Biology

Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI)

Jennifer E. Adair, Lindsay Androski, Lois Bayigga, Deus Bazira, Eugene Brandon, Lynda Dee, Steven Deeks, Mohammed Draz, Karine Dube, Mark Dybul, Umut Gurkan, Evelyn Harlow, Cissy Kityo, Michael Louella, Punam Malik, Vikram Mathews, Adrian McKemey, Henry Mugerwa, Daniel Muyanja, Olabimpe Olayiwola, Rimas J. Orentas, Alex Popovski, Jeff Sheehy, Francis Ssali, Moses Supercharger Nsubuga, John F. Tisdale, Els Verhoeyen, Boro Dropulic

Summary: The gene and cell therapy field has seen significant growth, but there is a geographical exclusion of low- and middle-income countries. To address this, the Global Gene Therapy Initiative aims to introduce clinical trials in Uganda and India.

GENE THERAPY (2023)

Article Immunology

Resolving the polygenic aetiology of a late onset combined immune deficiency caused by NFKB1 haploinsufficiency and modified by PIK3R1 and TNFRSF13B variants

Chantal E. Hargreaves, Fatima Dhalla, Arzoo M. Patel, Andres Caballero Garcia De Oteyza, Elizabeth Bateman, Joanne Miller, Consuelo Anzilotti, Lisa Ayers, Bodo Grimbacher, Smita Y. Patel

Summary: Genetic variants in PIK3CD, PIK3R1, and NFKB1 are known to cause primary immune deficiencies. This study identified a family with variations in NFKB1, TNFRSF13B, and PIK3R1, and aimed to describe their associated immune and cellular characteristics. The findings showed that mutant PIK3R1 resulted in increased basal pS6 signaling, while mutant NFKB1 did not have this effect.

CLINICAL IMMUNOLOGY (2022)

Correction Biochemistry & Molecular Biology

Towards access for all: 1st Working Group Report for the Global Gene Therapy Initiative (GGTI) (Sept, 10.1038/s41434-021-00284-4, 2021)

Jennifer E. Adair, Lindsay Androski, Lois Bayigga, Deus Bazira, Eugene Brandon, Lynda Dee, Steven Deeks, Mohamed Draz, Karine Dube, Mark Dybul, Umut Gurkan, Evelyn Harlow, Cissy Kityo, Michael Louella, Punam Malik, Vikram Mathews, Adrian McKemey, Henry Mugerwa, Daniel Muyanja, Olabimpe Olayiwola, Rimas J. Orentas, Alex Popovski, Jeff Sheehy, Francis Ssali, Moses Supercharger Nsubuga, John F. Tisdale, Els Verhoeyen, Boro Dropulic

GENE THERAPY (2023)

Article Hematology

Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation

Jenny N. H. G. Ho, Dominik Schmidt, Theresa Lowinus, Jeongmin Ryoo, Elaine-Pashupati Dopfer, Nicolas Gonzalo Nunez, Sara Costa-Pereira, Cristina Toffalori, Marco Punta, Viktor Fetsch, Tobias Wertheimer, Marie-Claire Rittmann, Lukas M. Braun, Marie Follo, Christelle Briere, Janaki Manoja Vinnakota, Marlene Langenbach, Felicitas Koppers, Khalid Shoumariyeh, Helena Engel, Tamina Ruckert, Melanie Marklin, Samuel Holzmayer, Anna L. Illert, Federica Magon, Geoffroy Andrieux, Sandra Duquesne, Dietmar Pfeifer, Julian Staniek, Marta Rizzi, Cornelius Miething, Natalie Kohler, Justus Duyster, Hans D. Menssen, Melanie Boerries, Joerg M. Buescher, Nina Cabezas-Wallscheid, Bruce R. Blazar, Petya Apostolova, Luca Vago, Erika L. Pearce, Burkhard Becher, Robert Zeiser

Summary: In this study, researchers found that inhibiting MDM2 can enhance the sensitivity of AML cells to cytotoxicity mediated by allogeneic T cells. MDM2 inhibitors can increase the expression of MHC class I and II in AML cells, improving the immunogenicity of the cells. Experiments in mouse and human samples confirmed the efficacy of MDM2 inhibitors.
Article Immunology

Disease Progression of WHIM Syndrome in an International Cohort of 66 Pediatric and Adult Patients

Christoph B. Geier, Maryssa Ellison, Rachel Cruz, Sumit Pawar, Alexander Leiss-Piller, Katarina Zmajkovicova, Shannon M. McNulty, Melis Yilmaz, Martin Oman Evans, Sumai Gordon, Boglarka Ujhazi, Ivana Wiest, Hassan Abolhassani, Asghar Aghamohammadi, Sara Barmettler, Saleh Bhar, Anastasia Bondarenko, Audrey Anna Bolyard, David Buchbinder, Michaela Cada, Mirta Cavieres, James A. Connelly, David C. Dale, Ekaterina Deordieva, Morna J. Dorsey, Simon B. Drysdale, Stephan Ehl, Reem Elfeky, Francesca Fioredda, Frank Firkin, Elizabeth Forster-Waldl, Bob Geng, Vera Goda, Luis Gonzalez-Granado, Eyal Grunebaum, Elzbieta Grzesk, Sarah E. Henrickson, Anna Hilfanova, Mitsuteru Hiwatari, Chihaya Imai, Winnie Ip, Soma Jyonouchi, Hirokazu Kanegane, Yuta Kawahara, Amer M. Khojah, Vy Hong-Diep Kim, Marina Kojic, Sylwia Koltan, Gergely Krivan, Daman Langguth, Yu-Lung Lau, Daniel Leung, Maurizio Miano, Irina Mersyanova, Talal Mousallem, Mica Muskat, Flavio A. Naoum, Suzie A. Noronha, Monia Ouederni, Shuichi Ozono, G. Wendell Richmond, Inga Sakovich, Ulrich Salzer, Catharina Schuetz, Filiz Odabasi Seeborg, Svetlana O. Sharapova, Katja Sockel, Alla Volokha, Malte von Bonin, Klaus Warnatz, Oliver Wegehaupt, Geoffrey A. Weinberg, Ke-Juin Wong, Austen Worth, Huang Yu, Yulia Zharankova, Xiaodong Zhao, Lisa Devlin, Adriana Badarau, Krisztian Csomos, Marton Keszei, Joao Pereira, Arthur G. Taveras, Sarah L. Beaussant-Cohen, Mei-Sing Ong, Anna Shcherbina, Jolan E. Walter

Summary: The study describes a cohort of 66 WHIM syndrome patients, including 57 previously unreported cases, with diverse clinical phenotypes. Mutations in the same region of the CXCR4 gene lead to hyperactive signaling. The age of diagnosis and onset of clinical manifestations of WHIM syndrome vary, with earlier detection and treatment leading to better outcomes, especially in patients with a family history of the syndrome.

JOURNAL OF CLINICAL IMMUNOLOGY (2022)

Review Pathology

Common Variable Immunodeficiency: More Pathways than Roads to Rome

Xiao P. Peng, Andres Caballero-Oteyza, Bodo Grimbacher

Summary: It has been 50 years since the introduction of the term common variable immunodeficiency (CVID), which has undergone numerous revisions in its understanding and application for diagnosis and management. The classification and definition of CVID remain controversial, but the expanded understanding of its genotypic and phenotypic overlap with other immunological conditions has been greatly enhanced by routine genotyping of CVID patients, which has revealed a diverse range of pathophysiological mechanisms. The lessons learned from CVID biology have greatly contributed to our understanding of both adaptive and innate immunity.

ANNUAL REVIEW OF PATHOLOGY-MECHANISMS OF DISEASE (2023)

Article Multidisciplinary Sciences

High antibody levels and reduced cellular response in children up to one year after SARS-CoV-2 infection

Eva-Maria Jacobsen, Dorit Fabricius, Magdalena Class, Fernando Topfstedt, Raquel Lorenzetti, Iga Janowska, Franziska Schmidt, Julian Staniek, Maria Zernickel, Thomas Stamminger, Andrea N. Dietz, Angela Zellmer, Manuel Hecht, Peter Rauch, Carmen Blum, Carolin Ludwig, Bernd Jahrsdoerfer, Hubert Schrezenmeier, Maximilian Heeg, Benjamin Mayer, Alina Seidel, Ruediger Gross, Jan Muench, Frank Kirchhoff, Sebastian F. N. Bode, Gudrun Strauss, Hanna Renk, Roland Elling, Maximillian Stich, Reinhard E. Voll, Burkhard Toenshof, Axel R. Franz, Philipp Henneke, Klaus-Michael Debatin, Marta Rizzi, Ales Janda

Summary: The severity and immune response of SARS-CoV-2 infection differ in adults and children. Children show a plasmablast-driven initial response, enhanced specific antibody response, and lower but detectable specific B and T cell responses compared to their parents. After one year, children exhibit an increase in S1-specific IgA class switch and enhanced T cell maturation.

NATURE COMMUNICATIONS (2022)

Article Oncology

Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia

Fabien Muselli, Lucas Mourgues, Nathalie Rochet, Marielle Nebout, Agnes Guerci, Els Verhoeyen, Adrien Krug, Laurence Legros, Jean-Francois Peyron, Didier Mary

Summary: Over the past two decades, three generations of Tyrosine Kinase Inhibitors (TKIs) have been developed to target the BCR::ABL1 oncoprotein to successfully treat chronic myeloid leukemia (CML). However, the daily administration of TKIs cannot be stopped to maintain a definitive remission state, resulting in unwanted side effects in the long term. New pharmacological approaches, such as the combination of bis-biguanides and TKIs, have been proposed to improve the sensitivity of TKI-insensitive leukemic stem cells (LSCs).

CANCERS (2023)

Article Immunology

The GAIN Registry - a New Prospective Study for Patients with Multi-organ Autoimmunity and Autoinflammation

Paulina Staus, Stephan Rusch, Sabine El-Helou, Gabriele Mueller, Mate Krausz, Ulf Geisen, Andres Caballero-Oteyza, Renate Krueger, Shahrzad Bakhtiar, Min Ae Lee-Kirsch, Maria Fasshauer, Ulrich Baumann, Bimba Franziska Hoyer, Joao Farela Neves, Michael Borte, Maria Carrabba, Fabian Hauck, Stephan Ehl, Peter Bader, Horst von Bernuth, Faranaz Atschekzei, Mikko R. J. Seppaenen, Klaus Warnatz, Alexandra Nieters, Gerhard Kindle, Bodo Grimbacher

Summary: Patient registries are important for studying rare diseases, and the GAIN consortium developed a dataset to address the challenges of multi-organ autoimmunity and autoinflammation. The dataset includes information on genetics, phenotypes, medication, and laboratory values. Twelve European centers have registered 419 patients with these conditions, providing a valuable resource for research.

JOURNAL OF CLINICAL IMMUNOLOGY (2023)

Article Cell Biology

AKT activity orchestrates marginal zone B cell development in mice and humans

Eva-Maria Cox, Mohamed El-Behi, Stefanie Ries, Johannes F. Vogt, Vivien Kohlhaas, Thomas Michna, Benoit Manfroi, Mona Al-Maarri, Florian Wanke, Boaz Tirosh, Corinne Pondarre, Harry Lezeau, Nir Yogev, Romy Mittenzwei, Marc Descatoire, Sandra Weller, Jean-Claude Weill, Claude-Agnes Reynaud, Pierre Boudinot, Luc Jouneau, Stefan Tenzer, Ute Distler, Anne Rensing-Ehl, Christoph Koenig, Julian Staniek, Marta Rizzi, Aude Magerus, Frederic Rieux-Laucat, F. Thomas Wunderlich, Nadine Hoevelmeyer, Simon Fillatreau

Summary: This study reveals that AKT is involved in the formation of marginal zone (MZ) B cells in both mice and humans. By manipulating AKT signaling in B cells and its impact on FoxO transcription factors, the AKT-FoxO axis is identified as a switch for MZ B cell formation in mice. This developmental pathway is conserved in humans, where AKT-dependent splenic IgD+CD27+ B cells are proposed as the equivalent of MZ B cells.

CELL REPORTS (2023)

Article Immunology

Next generation sequencing (NGS)-based approach to diagnosing Algerian patients with suspected inborn errors of immunity (IEIs)

Xiao P. Peng, Moudjahed Saleh Al-Ddafari, Andres Caballero-Oteyza, Chahrazed El Mezouar, Pavla Mrovecova, Saad Eddin Dib, Zoheir Massen, Mohammed Chems-Eddine Smahi, Alddafari Faiza, Rafik Terki Hassaine, Gerard Lefranc, Mourad Aribi, Bodo Grimbacher

Summary: The advent of next-generation sequencing technologies has enhanced our understanding of inborn errors of immunity (IEIs), but the presence of genetic variations among different populations necessitates tailoring diagnostic strategies to local demographics.

CLINICAL IMMUNOLOGY (2023)

Article Cell Biology

ARPC5 deficiency leads to severe early-onset systemic inflammation and mortality

Elena Sindram, Andres Caballero-Oteyza, Naoko Kogata, Shaina Chor Mei Huang, Zahra Alizadeh, Laura Gamez-Diaz, Mohammad Reza Fazlollhi, Xiao Peng, Bodo Grimbacher, Michael Way, Michele Proietti

Summary: The Arp2/3 complex is essential for the formation of branched actin networks. We identified a frameshift variant in the ARPC5 gene in a child with recurrent infections and birth defects. Loss of ARPC5 affects actin cytoskeleton organization and leads to developmental defects in mice. ARPC5 should be considered as a candidate gene for early-onset immunodeficiency.

DISEASE MODELS & MECHANISMS (2023)

Article Immunology

Human and mouse early B cell development: So similar but so different

Jakov Korzhenevich, Iga Janowska, Mirjam van der Burg, Marta Rizzi

Summary: This article reviews the similarities and differences in early B cell development between humans and mice, and provides a phenotypical classification of human and murine early progenitors and B cell stages based on protein expression. The role of key transcription factors and chemo- or cytokine signals during homeostatic and aberrant B lymphopoiesis in both species is critically compared.

IMMUNOLOGY LETTERS (2023)

Article Genetics & Heredity

Clinical, immunological and molecular findings of 8 patients with typical and atypical severe combined immunodeficiency: identification of 7 novel mutations by whole exome sequencing

Zahra Alizadeh, Mohammad Reza Fazlollahi, Marzieh Mazinani, Mohsen Badalzadeh, Hanieh Heydarlou, Raphael Carapito, Anne Molitor, Andres Caballero Garcia de Oteyza, Michele Proietti, Maryam Soleimani Bavani, Mansoureh Shariat, Morteza Fallahpour, Masoud Movahedi, Leila Moradi, Bodo Grimbacher, Seiamak Bahram, Zahra Pourpak

Summary: Severe combined immunodeficiency (SCID) is a severe inborn error of the immune system that can lead to life-threatening infections. This study describes the clinical manifestations and genetic results of four SCID and atypical SCID patients. The mutations identified in these patients expand the understanding of the clinical and molecular spectrum associated with SCID and provide valuable information for clinical management.

GENES AND IMMUNITY (2023)

Article Immunology

Telomere biology disorders may manifest as common variable immunodeficiency (CVID)

Benjamin Rolles, Andres Caballero-Oteyza, Michele Proietti, Sigune Goldacker, Klaus Warnatz, Nadezhda Camacho-Ordonez, Seraina Prader, Jana Pachlopnik Schmid, Margherita Vieri, Susanne Isfort, Robert Meyer, Martin Kirschner, Tim H. Bruemmendorf, Fabian Beier, Bodo Grimbacher

Summary: Telomere biology disorders (TBD) are genetic diseases caused by pathogenic variants in genes related to telomere maintenance. TBD can manifest in adulthood and have variable symptoms, making diagnosis complicated. Common variable immunodeficiency (CVID) is an antibody deficiency syndrome caused by dysfunctional B lymphocytes. In our study, we found that approximately 22% of CVID patients carried rare candidate variants in telomere-associated genes. We recommend including all TBD-associated genes in the genetic screening of patients with antibody deficiencies.

CLINICAL IMMUNOLOGY (2023)

暂无数据